AAPL 190.615 -3.2313% MSFT 356.3901 -3.0969% NVDA 95.26 -6.1385% GOOGL 146.34 -3.1887% GOOG 148.62 -3.0908% AMZN 165.59 -4.067% META 483.025 -3.6801% AVGO 161.805 -5.3717% LLY 809.03 -3.6823% TSLA 223.7399 -7.3042% TSM 147.28 -2.9392% V 318.115 -3.4875% JPM 227.27 -2.0219% UNH 430.0 -5.3093% NVO 58.005 -0.1291% WMT 91.56 -1.7807% LVMUY 107.85 -1.5428% XOM 104.42 -2.3382% LVMHF 538.5 -2.6221% MA 505.115 -2.3612%
CVS Health Corporation
CVS Health Corporation (NYSE: CVS) is a health solutions provider that operates through four main segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. The Health Care Benefits segment offers a variety of health insurance products and services, including traditional, voluntary, and consumer-directed options. These encompass medical, pharmacy, dental, and behavioral health plans, along with medical management services, Medicare Advantage and supplement plans, and Medicaid health care management services.
As per our previous report published on ‘CVS’ on 16th September 2024, Kalkine provided an ‘Buy’ stance on the stock at USD 57.98 based on fundamental analysis and the stock price has now moved by ~13.66% since then and is trading near resistance 2.
Noted below are the details of support and resistance levels provided in our previous report:
CVS’s Daily Chart
Considering the target level attainments, lower liquidity, reducing net income, downgrading operating efficiency, rising credit risk exposure, and increasing volatility over global equity market an ‘Sell’ rating is assigned to the ‘CVS’ at the closing market price of USD 65.90 as of Oct 08, 2024.
Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is Oct 08, 2024. The reference data in this report has been partly sourced from REFINITIV.
Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.
Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.
Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
Copyright © 2024 Krish Capital Pty Ltd. All rights reserved.
US
CA
NZ
UK
AU
IND
Please wait processing your request...